Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders preclinical and clinical studies

Planta Medica

Volumn 77, Issue 11, 2011, Pages 1123-1128

  Koch, Egon ^a   Malek, Fathi Abdul ^a  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

atherosclerosis; cardioprotection; cardiovascular diseases; Crataegus spp.; nitric oxide; restenosis; Rosaceae; vasoprotection

Indexed keywords

ALCOHOL; ATROPINE; CALCIUM ION; CARDIOTONIC AGENT; CARDIOVASCULAR AGENT; CATECHIN; CHOLESTEROL ACYLTRANSFERASE; CRATAEGUS EXTRACT; DIGOXIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPICATECHIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIMBACINE; HYPERIN; LACTATE DEHYDROGENASE; LEUKOCYTE ELASTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METHANOL; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC M2 RECEPTOR; NITRIC OXIDE; OUABAIN; PLACEBO; PROCYANIDIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RUTOSIDE; VERY LOW DENSITY LIPOPROTEIN; VITEXIN;

ADD ON THERAPY; ANTIARRHYTHMIC ACTIVITY; ATHEROSCLEROSIS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONOTROPISM; CLASTOGENICITY; COST BENEFIT ANALYSIS; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENZYME RELEASE; EXERCISE; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; FLOWER; GENOTOXICITY; GUINEA PIG; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REFRACTORY PERIOD; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MUTAGENICITY; NONHUMAN; PLANT LEAF; RESTENOSIS; REVIEW; SUBMAXIMAL EXERCISE CAPACITY; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CELL LINE; CRATAEGUS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FLAVONOIDS; FLOWERS; HEART; HUMANS; LIPID METABOLISM; MICE; PLANT EXTRACTS; PLANT LEAVES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; SIGNAL TRANSDUCTION;

CRATAEGUS; ROSACEAE;

EID: 79960708470     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1270849     Document Type: Review

References (62)

1. Koch E, Busse W R., Juretzek W, Chevts V. Hawthorn. Encyclopedia of dietary supplements, 2nd edition. New York Informa Healthcare 2010 411-422
2. European Pharmacopoeia 7.0, Vol. 1. Strasbourg Council of Europe 2007 1148-1151
3. Crataegi folium cum flore (hawthorn leaf and flower). ESCOP Monographs on the medicinal uses of plant drugs. Exeter European Scientific Cooperative on Phytotherapy 1999 1-11
4. Folium cum flore crataegi. WHO Monographs on selected medicinal plants. Geneva World Health Organization 2002 66-82
5. Kaul R. Der Weißdorn. Stuttgart Wissenschaftliche Verlagsgesellschaft 1998
6. Poepping S, Rose H, Ionescu I, Fischer Y, Kammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995 45 1157-1161
7. Siegel G, Casper U, Schnalke F, Hetzer R. Molecular physiological effector mechanisms of hawthorn extract in cardiac papillary muscle and coronary vascular smooth muscle. Phytother Res 1996 10 S195-S198
8. Schwinger R H., Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000 35 700-707 (Pubitemid 30253609)
9. Wang H, Haas M, Liang M, Cai T, Tian J, Li S, Xie Z. Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase. J Biol Chem 2004 279 17250-17259 (Pubitemid 38560483)
10. +-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations. J Biol Chem 2000 275 27838-27844
11. Arnon A, Hamlyn J M., Blaustein M P. Ouabain augments Ca(2+) transients in arterial smooth muscle without raising cytosolic Na(+). Am J Physiol Heart Circ Physiol 2000 279 H679-H691
12. Schmidt-Schweda S, von Burstin J, Möllmann H, Wollner S, Holubarsch C. Der positiv inotrope Effekt des Crataegus Spezialextrakt WS-1442 in isolierten Myozyten aus menschlichem Vorhof- und Ventrikelmyokard wird vorwiegend durch oligomere Procyanidine vermittelt. Z Kardiol 2000 89 (Suppl.5) 164
13. Müller A, Linke W, Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med 1999 65 335-339 (Pubitemid 29249907)
14. Joseph G, Zhao Y, Klaus W. Pharmakologisches Wirkprofil von Crataegus -Extrakt im Vergleich zu Epinephrin, Amrinon, Milrinon und Digoxin am isoliert perfundierten Meerschweinchenherzen. Arzneimittelforschung 1995 45 1261-1265 (Pubitemid 26022260)
15. Long S R., Carey R A., Crofoot K M., Proteau P J., Filtz T M. Effect of hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine 2006 13 643-650 (Pubitemid 44666402)
16. Salehi S, Long S R., Proteau P J., Filtz T M. Hawthorn (Crataegus monogyna Jacq.) extract exhibits atropine-sensitive activity in a cultured cardiomyocyte assay. J Nat Med 2009 63 1-8
17. Al Makdessi S, Sweidan H, Mullner S, Jacob R. Myocardial protection by pretreatment with Crataegus oxyacantha: an assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittelforschung 1996 46 25-27
18. Krzeminski T, Chatterjee S S. Ischemia and reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharm Pharmacol Lett 1993 3 45-48
19. Veveris M, Koch E, Chatterjee S S. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004 74 1945-1955 (Pubitemid 38167562)
20. Chatterjee S S., Koch E, Jaggy H, Krzeminski T. In-vitro- und In-vivo -Untersuchungen zur kardioprotektiven Wirkung von oligomeren Procyanidinen in einem Crataegus -Extrakt aus Blättern mit Blüten. Arzneimittelforschung 1997 47 821-825 (Pubitemid 27319881)
21. Jayachandran K S., Khan M, Selvendiran K, Devaraj S N., Kuppusamy P. Crataegus oxycantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways. J Cardiovasc Pharmacol 2010 56 526-531
22. Koch E, Spörl-Aich G. Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension. Planta Med 2006 72 1061
23. Hwang H S., Bleske B E., Ghannam M M., Converso K, Russell M W., Hunter J C., Boluyt M O. Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1 month of pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Drugs Ther 2008 22 19-28
24. Hwang H S., Boluyt M O., Converso K, Russell M W., Bleske B E. Effects of hawthorn on the progression of heart failure in a rat model of aortic constriction. Pharmacotherapy 2009 29 639-648
25. Bleske B E., Zineh I, Hwang H S., Welder G J., Ghannam M M., Boluyt M O. Evaluation of hawthorn extract on immunomodulatory biomarkers in a pressure overload model of heart failure. Med Sci Monit 2007 13 BR255-BR258 (Pubitemid 350272872)
26. Mävers W H., Hensel H. Veränderungen der lokalen Myokarddurchblutung nach oraler Gabe eines Crataegusextraktes bei nichtnarkotisierten Hunden. Arzneimittelforschung 1974 24 783-785
27. Koch E, Chatterjee S S. Crataegus extract WS-1442 enhances coronary flow in the isolated rat heart by endothelial release of nitric oxide. Naunyn Schmiedeberg's Arch Pharmacol 2000 361 R48
28. Brixius K, Willms S, Napp A, Tossios P, Ladage D, Bloch W, Mehlhorn U, Schwinger R H. Crataegus special extract WS 1442 induces an endothelium- dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther 2006 20 177-184 (Pubitemid 44099815)
29. Anselm E, Socorro V F., Dal-Ros S, Schott C, Bronner C, Schini-Kerth V B. Crataegus special extract WS 1442 causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of endothelial NO synthase but not via activation of estrogen receptors. J Cardiovasc Pharmacol 2009 53 253-260
30. Furst R, Zirrgiebel U, Totzke F, Zahler S, Vollmar A M., Koch E. The Crataegus extract WS 1442 inhibits balloon catheter-induced intimal hyperplasia in the rat carotid artery by directly influencing PDGFR-beta. Atherosclerosis 2010 211 409-417
31. Koch E, Chatterjee S S. Crataegus extract WS 1442 compensates the decrease of cardiac output in endotoxemic rats. Eur Cytokine Network 2000 11 527
32. Fürst R, Bubik M, Bihari P, Juergenliemk G, Ammer H, Krombach F, Zahler S, Vollmar A. The hawthorn special extract WS 1442 protects against endothelial barrier dysfunction elucidation of the underlying molecular mechanisms. Planta Med 2010 76 1191
33. Rajendran S, Deepalakshmi P D., Parasakthy K, Devaraj H, Devaraj S N. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996 123 235-241 (Pubitemid 26175078)
34. Shanthi R, Parasakthy K, Deepalakshmi P D., Niranjali D S. Protective effect of tincture of Crataegus on oxidative stress in experimental atherosclerosis in rats. J Clin Biochem 1996 20 211-223 (Pubitemid 27012418)
35. Zhang Z, Ho W K. K., Huang Y, Chen Z Y. Hypocholesterolemic activity of hawthorn fruit is mediated by regulation of cholesterol-7 -hydroxylase and acyl CoA: cholesterol acyltransferase. Food Res Int 2002 35 885-891 (Pubitemid 35224866)
36. Lin Y, Vermeer M A., Trautwein E A. Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters. Evid Based Complement Alternat Med 2011 article ID 801272
37. Koch E, Lanzendörfer-Goossens H, Weibezahn C. Crataegus extract WS 1442 inhibits apolipoprotein B100 (ApoB) secretion and increases low-density lipoprotein receptor (LDL-R) transcription in human HepG2 cells. Z Phytother 2006 27 S25-S26
38. Hecker-Niediek A. Untersuchungen zur Biogenese, Markierung und Pharmakokinetik der Procyanidine aus Crataegus-Spezies. Marburg Marburg University 1983
39. Liang M, Xu W, Zhang W, Zhang C, Liu R, Shen Y, Li H, Wang X, Pan Q, Chen C. Quantitative LC/MS/MS method and in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactive constituent on cardiovascular system from hawthorn. Biomed Chromatogr 2007 21 422-429 (Pubitemid 46577849)
40. Ma L Y., Liu R H., Xu X D., Yu M Q., Zhang Q, Liu H L. The pharmacokinetics of C-glycosyl flavones of hawthorn leaf flavonoids in rat after single dose oral administration. Phytomedicine 2010 17 640-645
41. Schlegelmilch R, Heywood R. Toxicity of Crataegus (hawthorn) extract (WS 1442). J Am Coll Toxicol 1994 13 103-111 (Pubitemid 24134286)
42. Yao M, Ritchie H E., Brown-Woodman P D. A reproductive screening test of hawthorn. J Ethnopharmacol 2008 118 127-132
43. Loew D. Phytotherapy in heart failure. Phytomedicine 1997 4 267-271 (Pubitemid 127565776)
44. Hawthorn leaf with flower. The Complete German Commission E Monographs. Boston Integrative Medicine Communications 1998 142-144
45. Pittler M H., Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008 (1) CD005312
46. Zick S M., Vautaw B M., Gillespie B, Aaronson K D. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial. Eur J Heart Fail 2009 11 990-999
47. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002 143 910-915 (Pubitemid 34595353)
48. Eichstädt H, Störk T, Möckel M, Danne O, Funk P, Köhler S. Wirksamkeit und Verträglichkeit von Crataegus- Extrakt WS 1442 bei herzinsuffizienten Patienten mit eingeschränkter linksventrikulärer Funktion. Perfusion 2001 14 212-217 (Pubitemid 33786715)
49. Zapfe Jr G. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine 2001 8 262-266
50. Förster A, Förster K, Bühring M, Wolfstädter H D. Crataegus bei mäßig reduzierter linksventrikulärer Auswurffraktion. Münch Med Wschr 1994 136 S21-S26
51. Schmidt U, Kuhn U, Ploch M, Hübner W D. Efficacy of hawthorn (Crataegus) preparation LI132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994 1 17-24
52. Boedigheimer K, Chase D. Wirksamkeit von Weissdorn-Extrakt in der Dosierung 3mal 100mg täglich. Multizentrische Doppelblindstudie mit 85 herzinsuffizienten Patienten im Stadium NYHA II. Münch Med Wschr 1994 136 7-11
53. Weikl A, Assmus K D., Neukum-Schmidt A, Schmitz J, Zapfe G, Noh H S., Siegrist J. Crataegus -Spezialextrakt WS-1442. Objektiver Wirksamkeitsnachweis bei Patienten mit Herzinsuffizienz (NYHA II). Fortschr Med 1996 114 291-296
54. Leuchtgens H. Crataegus -Spezialextrakt WS-1442 bei Herzinsuffizienz NYHA II. Eine plazebokontrollierte randomisierte Doppelblindstudie. Fortschr Med 1993 111 352-354
55. Weikl A, Noh H S. Der Einfluss von Crataegus bei globaler Herzinsuffizienz. Herz Gefässe 1992 12 516-524
56. Eichstädt H, Bäder M, Danne O, Kaiser W, Stein U, Felix R. Crataegus -Extrakt hilft dem Patienten mit NYHA II-Herzinsuffizienz: Untersuchung der myokardialen und hämodynamischen Wirkung eines standardisierten Crataegus -Präparates mit Hilfe computergestützter Radionuklidventrikulographie. Therapiewoche 1989 39 3288-3296
57. Koller M, Lorenz W, Aubke W, Jensen A, Gerlach F M., Kühl J, Pfeil T, Regitz-Zagrosek V, Rusche H, Rychlik R. Weissdorn-Spezialextrakt in der Therapie früher Stadien der KHK-assoziierten Herzinsuffizienz. MMW Fortsch Med 2005 147 159-164
58. Holubarsch C J., Colucci W S., Meinertz T, Gaus W, Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008 10 1255-1263
59. Walker A F., Marakis G, Simpson E, Hope J L., Robinson P A., Hassanein M, Simpson H C. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2006 56 437-443 (Pubitemid 43891226)
60. Daniele C, Mazzanti G, Pittler M H., Ernst E. Adverse-event profile of Crataegus spp.: a systematic review. Drug Saf 2006 29 523-535 (Pubitemid 43855083)
61. Asher G N. Herbal products review. What do we really know? J Am Coll Cardiol 2010 56 903
62. Tankanow R, Tamer H R., Streetman D S., Smith S G., Welton J L., Annesley T, Aaronson K D., Bleske B E. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003 43 637-642 (Pubitemid 36613122)